BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

288 related articles for article (PubMed ID: 30145748)

  • 21. Efficacy of adjuvant therapy with 3.7 GBq radioactive iodine in intermediate-risk patients with 'higher risk features' and predictive value of postoperative nonstimulated thyroglobulin.
    Rosario PW; Mourão GF; Calsolari MR
    Nucl Med Commun; 2016 Nov; 37(11):1148-53. PubMed ID: 27341413
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Papillary thyroid cancer: factors involved in restaging N1 disease after total thyroidectomy and radioactive iodine treatment.
    Guy A; Hirsch D; Shohat T; Bachar G; Tirosh A; Robenshtok E; Shimon I; Benbassat CA
    J Clin Endocrinol Metab; 2014 Nov; 99(11):4167-73. PubMed ID: 25157544
    [TBL] [Abstract][Full Text] [Related]  

  • 23. High-Dose RAI Therapy Justified by Pathological N1a Disease Revealed by Prophylactic Central Neck Dissection for cN0 Papillary Thyroid Cancer Patients: Is it Superior to Low-Dose RAI Therapy?
    Wei L; Bai L; Zhao L; Yu T; Ma Q; Ji B
    World J Surg; 2019 May; 43(5):1256-1263. PubMed ID: 30684002
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Clinical Outcomes of N1b Papillary Thyroid Cancer Patients Treated with Two Different Doses of Radioiodine Ablation Therapy.
    Jin M; Ahn J; Lee YM; Sung TY; Kim WG; Kim TY; Ryu JS; Kim WB; Shong YK; Jeon MJ
    Endocrinol Metab (Seoul); 2020 Sep; 35(3):602-609. PubMed ID: 32981302
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Comparable Ablation Efficiency of 30 and 100 mCi of I-131 for Low to Intermediate Risk Thyroid Cancers Using Triple Negative Criteria.
    Fatima N; Zaman MU; Zaman A; Zaman U; Tahseen R
    Asian Pac J Cancer Prev; 2016; 17(3):1115-8. PubMed ID: 27039734
    [TBL] [Abstract][Full Text] [Related]  

  • 26. BRAF
    Cao J; Chen B; Zhu X; Sun Y; Li X; Zhang W; Wang X
    Endocrine; 2024 Apr; 84(1):160-170. PubMed ID: 37851243
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A randomized clinical trial comparing 50mCi and 100mCi of iodine-131 for ablation of differentiated thyroid cancers.
    Zaman Mu; Toor R; Kamal S; Maqbool M; Habib S; Niaz K
    J Pak Med Assoc; 2006 Aug; 56(8):353-6. PubMed ID: 16967785
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Adjuvant radioactive therapy after reoperation for locoregionally recurrent papillary thyroid cancer in patients who initially underwent total thyroidectomy and high-dose remnant ablation.
    Yim JH; Kim WB; Kim EY; Kim WG; Kim TY; Ryu JS; Moon DH; Sung TY; Yoon JH; Kim SC; Hong SJ; Shong YK
    J Clin Endocrinol Metab; 2011 Dec; 96(12):3695-700. PubMed ID: 21976723
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Radioactive iodine ablation does not prevent recurrences in patients with papillary thyroid microcarcinoma.
    Kim HJ; Kim NK; Choi JH; Kim SW; Jin SM; Suh S; Bae JC; Min YK; Chung JH; Kim SW
    Clin Endocrinol (Oxf); 2013 Apr; 78(4):614-20. PubMed ID: 22957654
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Higher adjuvant radioactive iodine therapy dosage helps intermediate-risk papillary thyroid carcinoma patients achieve better therapeutic effect.
    Li X; Zheng H; Ma C; Ji Y; Wang X; Sun D; Meng Z; Zheng W
    Front Endocrinol (Lausanne); 2023; 14():1307325. PubMed ID: 38298190
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The clinical meaning of pre- and post-ablation thyroglobulin levels at first radioiodine therapy in patients with papillary thyroid cancer.
    Kim HK; Yoon JH; Cho JS; Kwon SY; Yoo SW; Kang HC
    Korean J Intern Med; 2020 Sep; 35(5):1164-1172. PubMed ID: 31352718
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Dynamic Risk Estimates of Outcome in Chinese Patients with Well-Differentiated Thyroid Cancer After Total Thyroidectomy and Radioactive Iodine Remnant Ablation.
    Shen FC; Hsieh CJ; Huang IC; Chang YH; Wang PW
    Thyroid; 2017 Apr; 27(4):531-536. PubMed ID: 28007013
    [TBL] [Abstract][Full Text] [Related]  

  • 33. In search of an unstimulated thyroglobulin baseline value in low-risk papillary thyroid carcinoma patients not receiving radioactive iodine ablation.
    Angell TE; Spencer CA; Rubino BD; Nicoloff JT; LoPresti JS
    Thyroid; 2014 Jul; 24(7):1127-33. PubMed ID: 24697314
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Impact of cervical lymph node dissection on serum TG and the course of disease in TG-positive, radioactive iodine whole body scan-negative recurrent/persistent papillary thyroid cancer.
    Alzahrani AS; Raef H; Sultan A; Al Sobhi S; Ingemansson S; Ahmed M; Al Mahfouz A
    J Endocrinol Invest; 2002 Jun; 25(6):526-31. PubMed ID: 12109624
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Outpatient ablation treatment with two doses of 30 mCi of radioactive iodine for non-low-risk papillary thyroid cancer.
    Uno A; Takeda H; Mori M; Yamamoto Y; Takenaka Y; Enomoto K; Takeda N
    J Med Invest; 2023; 70(1.2):17-21. PubMed ID: 37164716
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Is empirical radioactive iodine therapy still a valid approach to patients with thyroid cancer and elevated thyroglobulin?
    Rosario PW; Mourão GF; dos Santos JB; Calsolari MR
    Thyroid; 2014 Mar; 24(3):533-6. PubMed ID: 24067080
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Anti-thyroglobulin antibodies do not significantly increase the risk of finding iodine avid metastases on post-radioactive iodine ablation scan in low-risk thyroid cancer patients.
    Nabhan F; Porter K; Senter L; Ringel MD
    J Endocrinol Invest; 2017 Sep; 40(9):1015-1021. PubMed ID: 28510122
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Risk factors for radioactive iodine-avid metastatic lymph nodes on post I-131 ablation SPECT/CT in low- or intermediate-risk groups of papillary thyroid cancer.
    Lee CH; Jung JH; Son SH; Hong CM; Jeong JH; Jeong SY; Lee SW; Lee J; Ahn BC
    PLoS One; 2018; 13(8):e0202644. PubMed ID: 30118516
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Factors Predicting Early Release of Thyroid Cancer Patients from the Isolation Room after Radioiodine-131 Treatment.
    Fatima N; Zaman Mu; Zaman A; Zaman U; Tahseen R; Shahid W
    Asian Pac J Cancer Prev; 2016; 17(1):125-9. PubMed ID: 26838196
    [TBL] [Abstract][Full Text] [Related]  

  • 40. An enhanced treatment effect can be expected from a higher serum thyroglobulin level after radioactive iodine therapy.
    Choi JH; Lim I; Lee I; Byun BH; Kim BI; Choi CW; Lim SM
    Ann Nucl Med; 2019 Feb; 33(2):128-134. PubMed ID: 30382500
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.